Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3454738 · 2 trials · 2 indications
PK: Cmax of LY3454738
PK: AUC of LY3454738
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
The vIGA-AD measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification
| Arm | Type | Description |
|---|---|---|
| LY3454738 (Test Formulation) | EXPERIMENTAL | - |
| LY3454738 (Reference Formulation) | EXPERIMENTAL | - |
| LY3454738 - Part A | EXPERIMENTAL | Escalating doses of LY3454738 administered intravenously (IV) or subcutaneously (SC) to healthy participants |
| Placebo - Part A | PLACEBO_COMPARATOR | Placebo administered IV to healthy participants |
| LY3454738 - Part B | EXPERIMENTAL | LY3454738 administered IV to healthy participants |
| Placebo - Part B | PLACEBO_COMPARATOR | Placebo administered IV to healthy participants |
| LY3454738 - Part C | EXPERIMENTAL | LY3454738 administered IV to participants with atopic dermatitis (AD) |
| Placebo - Part C | PLACEBO_COMPARATOR | Placebo administered IV to participants with AD |
| Name | Type | Description |
|---|---|---|
| LY3454738 | DRUG | Administered subcutaneously (SC) |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Participants who are overtly healthy as determined by medical history and physical examination. * Have body mass index (BMI) between 18.0 and 28.0 kilograms per meter squared (kg/m²), inclusive, at screening. Exclusion Criteria: * Have a significant history of or current car...
LY3454738 is an investigational small molecule being studied for atopic dermatitis. It has been evaluated in clinical trials involving healthy participants and participants with atopic dermatitis. The drug is in Phase 1 development and is not approved by the FDA.
LY3454738 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker LLY. The drug is currently in Phase 1 clinical development for atopic dermatitis.
LY3454738 is in Phase 1 clinical development. It has completed two Phase 1 trials, including one in healthy participants and participants with atopic dermatitis, and another relative bioavailability study in healthy participants. The drug remains investigational.
LY3454738 has been studied in two completed Phase 1 trials. NCT03750643 evaluated the drug in healthy participants and participants with atopic dermatitis, enrolling 128 participants in the United States and Puerto Rico. NCT06173895 was a relative bioavailability study in 30 healthy participants in the United States.
LY3454738 is the drug name used in clinical trials for this investigational small molecule. No alternative names have been reported for this compound in the available clinical trial information.